Drug Profile
Tranexamic acid - Hyundai Pharmaceutical
Alternative Names: HTB-003Latest Information Update: 14 Oct 2021
Price :
$50
*
At a glance
- Originator Hyundai Pharmaceutical
- Class Amines; Anti-infectives; Anti-inflammatories; Antifibrinolytics; Antihaemorrhagics; Cardiovascular therapies; Cyclohexanecarboxylic acids; Skin disorder therapies; Small molecules
- Mechanism of Action Plasminogen activator inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Melanosis
Most Recent Events
- 18 Jan 2018 Discontinued - Phase-III for Melanosis in South Korea (Topical)
- 07 Dec 2015 Phase-III clinical trials in Melanosis in South Korea (unspecified route) prior to December 2015